CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±è¹Ì³ª
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£Àå, °£¾Ï
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
20 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol. 2019 Oct 8:1-8. [Epub ahead of print]  
19 ÇØ¿Ü Kim MN (1ÀúÀÚ, ±³½ÅÀúÀÚ), Lee JH, Chon YE, Ha Y, Hwang SG. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. Eur J Gastroenterol Hepatol. 2019 Sep 3. [Epub ahead of print]  
18 ÇØ¿Ü Kim MN (1ÀúÀÚ, ±³½ÅÀúÀÚ), Lee SM, Kim JS, Hwang SG. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2019 Oct;84(4):809-817.  
17 ÇØ¿Ü Kim MN (1ÀúÀÚ), Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver. 2019 Mar 15;13(2):197-205.  
16 ÇØ¿Ü Kim MN (1ÀúÀÚ), Hwang SG, Rim KS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU.Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.Liver Int. 2017 Dec;37(12):1788-1795.  
15 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Song KJ, Park YN, Han KH. Increased risk of Hepatocellular carcinoma in Chronic hepatitis B patients with Transient elastography-defined Subclinical cirrhosis. Hepatology 2015.Jun;61(6):1851-9.  
14 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim JO, Lee SM, Hwang SG, Kim NK. Variation in the Dicer and RAN genes are associated with survival in patients with hepatocellular carcinoma. 2016 PLOS One 2016 Sep 9;11(9):e0162279.  
13 ÇØ¿Ü Kim MN (1ÀúÀÚ), Kim HS, Kim JK, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH. Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. J Korean Med Sci. 2016 Sep;31(9).  
12 ÇØ¿Ü Kim MN (1ÀúÀÚ), Park JY, Ahn SH, Kim BK, Kim SU, Kim DY, Han KH. Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. J Med Virol 2016 Jun 30 [Epub ahead of print]  
11 ÇØ¿Ü Seo YS, Kim MN (°øµ¿ 1ÀúÀÚ), Kim SU, Kim SG, Um SH, Han KH, Kim YS. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. Medicine (Baltimore). 2016 Mar;95(12):e2985.  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729